Clinical Trials Browser

tucatinib × 90 days × Clear all

NCT06157892 2026-03-17

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Phase 2 Recruiting

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05132582 2026-03-16

HER2CLIMB-05

Phase 3 Active not recruiting

Breast Neoplasms

NCT05253651 2026-03-16

MOUNTAINEER-03

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05382364 2026-03-12

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

Phase 1 Active not recruiting

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT07413939 2026-03-10

BREnnA

Phase 2/3 Not yet recruiting

HER2-positive Breast Cancer

NCT03297606 2026-03-04

CAPTUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT05672524 2026-03-04

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Rectal Neoplasms

NCT07318389 2026-02-27

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

Phase EARLY_PHASE1 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Phase 2 Active not recruiting

40 enrolled 67 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06016387 2026-02-23

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

Phase 2 Recruiting

Breast Neoplasms, Meningeal Neoplasms

NCT07193394 2026-02-23

H3RAKLES

Phase 2 Recruiting

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02693535 2026-02-13

TAPUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT06686394 2026-02-13

MK-1022-009

Phase 1/2 Recruiting

Breast Neoplasms

NCT05062889 2026-02-03

ERASE-CRC

Phase 2 Suspended

Gastrointestinal

Colonic Neoplasms

NCT04721977 2026-01-09

MK-7119-001

Phase 2 Active not recruiting

66 enrolled 7 charts

Breast Neoplasms

NCT06961331 2026-01-09

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

Breast Neoplasms

NCT05553522 2025-12-31

Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

Phase 1 Terminated

Brain Neoplasms